| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Epidermal growth factor receptor (EGFR) is known as a key target molecule for cancer therapy because ligand binding to EGFR and its signal pathway leads to cancer cell proliferation, invasion, metastasis, angiogenesis, avoidance of apoptosis. So, blocking antibody for EGFR is now become an important therapeutic agent for cancer treatment.
We developed artificial bispecific antibody that binds both EGFR and CD3 which is a surface marker of human lymphocyte. This antibody can not only block the EGFR signal but also lead lymphocytes to cancer cells. We found that this artificial antibody had a very strong anticancer activity for EGFR positive cancer cells.
|
